Q-omics provides the consensus-scored MEOX2 profile across patient tissues and cancer cell-line models. MEOX2 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, MEOX2 is differentially expressed in 14, with the highest sampling consensus in THCA. Additionally, MEOX2 RNA expression shows 24,266 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight KIRP, THCA, and LSCC as cancer lineages where MEOX2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MEOX2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MEOX2 survival associations across molecular data types. MEOX2 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (7) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MEOX2 RNA expression–survival associations across cancer types. High MEOX2 expression shows unfavorable associations in KIRP, OV, BLCA, ACC and LGG, but favorable associations in LUAD. The KIRP Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRP as the clearest survival context for MEOX2 RNA expression.
This table summarizes MEOX2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14, while mass-spec protein shows differences in 3. The strongest signals are observed in THCA for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for MEOX2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MEOX2 shows lower tumor expression in THCA, KICH, BLCA, UCEC and LUSC and higher tumor expression in LIHC. The THCA box plot shows higher MEOX2 RNA expression in normal versus tumor tissue (log2 FC = −2.515, t-test p < 0.001).
This table shows molecular features associated with MEOX2 in patient tissues and cancer cell lines. In patient samples, MEOX2 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, MEOX2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in KIDNEY, while CRISPR and shRNA rows add functional-dependency signals in OVARY and BLOOD_Leukemia.
